TELO News and Press, Telomir Pharmaceuticals Inc. From 02/05/26

Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic mechanisms. MIAMI, FLORIDA / ACCESS Newswire / February 5, 2026 / Telomir Pharmac...

Zurn Elkay Water Solutions Corporation (ZWS) is expected to report $0.34 for Q4 2025 XPLR Infrastructure LP representing limited partner interests (XIFR) is expected to report $-0.9 for Q4 2025 Sun Country Airlines Holdings Inc. (SNCY) is expected to report $0.11 for Q4 2025 American ...

2026-01-05 09:51:14 ET Telomir Pharmaceuticals (NASDAQ: TELO) , a preclinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of disease, announced positive results from a completed efficacy study evaluating Telomir...

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread. MIAMI, FLORIDA / ACCESS Newswire / January 5, 2026 / Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"...

2025-12-18 09:35:00 ET Telomir Pharmaceuticals (NASDAQ: TELO) announced favorable results from a comprehensive series of IND-enabling Good Laboratory Practice toxicology and safety pharmacology studies for its lead therapeutic candidate Telomir-1 (Zn-Telomir), reporting no treatment-rel...

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-sta...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November 25, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a ...

Findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. MIAMI, FL / ACCESS Newswire / November 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telo...

New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating activity - key to its broader epigenetic mechanism of action. MIAMI, FL / ACCESS Newswir...

Ensysce Biosciences Inc. (ENSC) is expected to report $-0.85 for Q3 2025 IO Biotech Inc. (IOBT) is expected to report $-0.31 for Q3 2025 Lifeward Ltd. (LFWD) is expected to report $-0.14 for Q3 2025 Life360 Inc. (LIF) is expected to report $0.03 for Q3 2025 Pixelworks Inc. (PXLW) ...